Latest news for Ono Pharmaceutical (OTC:OPHLF) Stock

Ono Pharmaceutical is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a global business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.

News

Eurozone

Futures

Global

Pre-Market Outlook

Markets

COST

CTRP

KNOP

KYKOF

OPHLF

TOUR

US Stock Futures Edge Lower Ahead Of Federal Budget

ONO PHARMACEUTICAL by Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co Ltd

Fate Therapeutics: Not Now, Maybe Never?

Twist Bioscience in pact with Japan-based Ono for autoimmune antibodies

Merus Stock: Rally Seems Overdone

Ono Pharmaceutical GAAP EPS of ¥229.06, revenue of ¥389.91B

Ono Pharmaceutical reports FY results

Ono Pharmaceutical Co., Ltd. (OPHLF) Q1 2024 Earnings Call Transcript

ONO Pharmaceutical Co (JP:4528) has released an update. Ono Pharmaceutical Co., Ltd. is prioritizing corporate governance by increasing management ...

Ono Pharmaceutical Advances Governance and Diversity

FATE

INCY

MRUS

OPHLY

TWST

Press Releases

Acromegaly Pipeline, Clinical Trials Assessment, FDA Approvals, and Emerging Drugs 2023 (Updated)

AQST

ATHJF

CAMX

CRNX

IONS

RANI

SBBP

Ono Pharmaceutical

<a href="http://asia.nikkei.com/Japan-Update/Ono-Pharmaceutical-readies-heavy-dose-of-US-acquisitions" title="http://asia.nikkei.com/Japan-Update/Ono-Pharmaceutical-readies-heavy-dose-of-US-acquisitions">http://asia.nikkei.com/Japan-Update/Ono-Pharmaceutical-readies-heavy-dose-of-US-acquisitions</a>

Rumors

Ono Pharmaceutical to Spend Up to $4.44B on US Acquisitions Over Next Five Years -Nikkei

Pre-open movers

US stock futures traded slightly lower in early pre-market trade. The US Treasury monthly budget report for November will be released at 2:00 p.m. ET. Futures for the Dow Jones Industrial Average dropped 12 points to 17,768.00, while the Standard & Poor's 500 index futures fell 1.60 points to 2,055.90. Futures for the Nasdaq 100 index dropped 2.75 points to 4,288.00.

A Peek Into Global Markets

 
European markets were higher today, with the Spanish Ibex Index rising 0.45%, STOXX Europe 600 Index gaining 0.39%. German DAX 30 index climbed 0.64%, French CAC 40 Index jumped 0.35% and London's FTSE 100 Index rose 0.13%. UK trade deficit for goods narrowed to 9.6 billion pounds ($15.1 billion) in October, versus a revised GBP10.5 billion in September.

In Asian markets, Japan's Nikkei Stock Average fell 2.25%, Hong Kong's Hang Seng Index rose 0.16%, China's Shanghai Composite Index climbed 2.93% and India's Sensex rose 0.12%.

Broker Recommendation
Analysts at BMO Capital upgraded American Eagle Outfitters (NYSE: <a class="ticker" href="/stock/aeo#NYSE">AEO</a>) from Market Perform to Outperform. The price target for American Eagle has been raised from $12 to $15. 

American Eagle's shares closed at $12.51 yesterday.

Breaking news 
<ul>
<li> Costco Wholesale (NASDAQ: <a class="ticker" href="/stock/cost#NASDAQ">COST</a>) reported a better-than-expected profit for the first quarter. To read the full news, <a href="http://www.benzinga.com/news/earnings/14/12/5069872/update-costco-q1-profit-tops-expectations">click here. </a></li>
 
<li> Ono Pharmaceutical Co (OTC: <a class="ticker" href="/stock/ophlf#OTC">OPHLF</a>), Bristol-Myers Squibb Company (NYSE: <a class="ticker" href="/stock/bmy#NYSE">BMY</a>) and Kyowa Hakko Kirin Co (OTC: <a class="ticker" href="/stock/kykof#OTC">KYKOF</a>) announced today the companies have entered into a clinical trial collaboration agreement to conduct a Phase 1 combination study with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, and mogamulizumab, an anti-CCR4 antibody. To read the full news, <a href="http://www.benzinga.com/pressreleases/14/12/b5069805/ono-pharmaceutical-bristol-myers-squibb-and-kyowa-hakko-kirin-announce-">click here.</a></li>
 
<li> KNOT Offshore Partners LP (NYSE: <a class="ticker" href="/stock/knop#NYSE">KNOP</a>) announced today that its wholly owned subsidiary, KNOT Shuttle Tankers AS, had entered into a share purchase agreement to acquire KNOT Shuttle Tankers 20 AS, the company that owns the shuttle tanker Dan Cisne, from Knutsen NYK Offshore Tankers AS for a purchase price of $103.0 million less approximately $82.1 million of existing bank debt related to the Dan Cisne. To read the full news, <a href="http://www.benzinga.com/pressreleases/14/12/b5069721/knot-offshore-partners-lp-announces-entry-into-agreement-to-acquire-dan">click here.</a></li>
 
<li> Tuniu (NASDAQ: <a class="ticker" href="/stock/tour#NASDAQ">TOUR</a>) today announced that the Company has signed a strategic agreement with Ctrip.com International (NASDAQ: <a class="ticker" href="/stock/ctrp#NASDAQ">CTRP</a>) to expand their collaboration on shared travel resources. To read the full news, <a href="http://www.benzinga.com/pressreleases/14/12/g5069694/tuniu-and-ctrip-sign-strategic-collaboration-agreement">click here.</a></li>
</ul>

Ono Pharmaceutical Co.,Ltd. (OTC: <a class="ticker" href="/stock/ophlf#OTC">OPHLF</a>), Bristol-Myers 
 Squibb Company (NYSE: <a class="ticker" href="/stock/bmy#NYSE">BMY</a>) and Kyowa 
 Hakko Kirin Co., Ltd. (OTC: <a class="ticker" href="/stock/kykof#OTC">KYKOF</a>) announced 
 today the companies have entered into a clinical trial collaboration 
 agreement to conduct a Phase 1 combination study with Opdivo 
 (nivolumab), a PD-1 immune checkpoint inhibitor, and mogamulizumab, an 
 anti-CCR4 antibody. The study, which will be conducted in Japan, will 
 focus on evaluating the safety, tolerability and anti-tumor activity of 
 combining Opdivo and mogamulizumab as a potential treatment 
 option for patients with advanced or metastatic solid tumors.
 
 
 Opdivo, launched in Japan in September 2014 for the treatment of 
 patients with unresectable melanoma, is being developed in multiple 
 

 <a href="http://www.benzinga.com/pressreleases/14/12/b5069805/ono-pharmaceutical-bristol-myers-squibb-and-kyowa-hakko-kirin-announce-">See full press release</a>

Contracts

Legal

Ono Pharmaceutical, Bristol-Myers Squibb, Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo and Mogamulizumab in Advanced Solid Tumors

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Ono Pharmaceutical

News

Latest news for Ono Pharmaceutical (OTC:OPHLF) Stock

Friday, February 03, 2017

Wednesday, December 10, 2014